Key result
Pediatric heart failure pharmacotherapy relies largely on adult extrapolation amid limited pediatric trial evidence.
Why the study?
Evidence supporting pharmacological therapy in pediatric heart failure remains scarce and inconclusive, leading to treatment mostly extrapolated from adult studies despite developmental differences and etiological heterogeneity.
Highlights the critical evidence gap in pediatric heart failure pharmacotherapy and the need for dedicated pediatric clinical trials.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Our adult heart failure colleagues have developed different treatment strategies based on heart failure subtypes. We need to do the same in pediatrics. By identifying the subtypes, we can develop more specific approaches to their management.”
“Many children diagnosed with heart failure will need a heart transplant before they turn five or in the worst cases almost a third will die within a year. However, the disease is largely managed with treatments approved for adults, based on data from adult studies.”
“Finding ways to make new treatment options available for children sooner is a high priority for the FDA. This draft guidance will help drug companies improve the efficiency of developing certain medicines for children. It also will help to ensure children only participate in clinical trials when necessary to further the scientific understanding of a medical product's use in children.”
Pediatric HF pharmacotherapy requires cautious adult-data extrapolation; leaves open the urgent need for dedicated pediatric RCTs.
Heart failure (HF) is a complex clinical syndrome that represents an increasingly relevant health issue, associated with substantial morbidity and mortality in pediatric patients. While considerable therapeutic advances have transformed the prognosis of adult patients with heart failure over the past three decades, progress in pediatric heart failure has been considerably slower. In adult patients, large randomized controlled trials (RCTs) have established angiotensin-converting enzyme inhibitors (ACE inhibitors), beta-blockers, mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and, more recently, sodium-glucose cotransporter-2 (SGLT2) inhibitors as the cornerstone of guideline-directed medical therapy. Evidence supporting pharmacological therapy in pediatric heart failure remains scarce and frequently inconclusive, with most available studies being limited by small sample sizes and heterogeneous patient populations. Therefore, heart failure treatment in children is mostly extrapolated from adult studies and guidelines. However, developmental differences in myocardial structure and function, neurohormonal signaling, pharmacokinetics and pharmacodynamics may substantially influence therapeutic response. In addition, the rarity and the etiological heterogeneity of pediatric HF create major methodological challenges for adequately powered clinical trials. This review compares the pharmacological management of HF in adult and pediatric populations, examines the strength of evidence for contemporary therapies and discusses the biological and methodological limitations of translating adult evidence into pediatric practice. Multicenter collaborative studies and well-designed pediatric randomized controlled trials are essential for establishing truly evidence-based pharmacological strategies for children with HF.
No takes yet. Share an insight, caveat, or question.
Sorescu et al. (2026) conducted a review in Pediatric Heart Failure. Pharmacological therapy was evaluated. Pharmacological management of pediatric heart failure relies largely on extrapolation from adult studies due to a lack of robust pediatric randomized controlled trials.
Synapse has enriched 10 related papers. Consider them for comparative context: